Member Info for CHELSEA7

Indeed we could.

I have just used Vulpes as an example, hopefully somebody else will take a stake, and the 6p price is just an example too if it were to be Vulpes. Hoping as you it is somebody else, and I am pretty sure Scancell are too, would they really want one shareholder to own as much as 30%??

6.50/7.10

+.74%, no corresponding trade.......yet, augurs well.

Taking 150k at 6.733, slightly up on Friday, lets have a blue day and week.

6.50/7...............same as Fridays close, lets have a great week. Just reminded myself that last May we were 3.8p and two months later with Vulpes coming in 9.75p, so IMHO, nothing to fear about a raising at all.

Freddieboy, morning. Just seen this RNS from Regency Mines...................

Director Legacy Remuneration Shares and Issue of Warrants



Nigel Burton and Ewen Ainsworth joined Regency Mines as a Director on 24 June 2019 under an arrangement where 42.5% and 48.6% of their respective annual Directors' fee was to be paid in shares. Accordingly, to clear historic balances the Company has issued 122,312 new ordinary shares to Mr. Burton and 190,929 new ordinary shares to Mr Ainsworth for the period from June 2019 to December 2019 (of the 190,929 shares awarded to Mr Ainsworth, 141,901 new ordinary shares have been issued to Discovery Energy Limited a company controlled by Mr Ainsworth). This deals with all outstanding legacy issues and the Non-Executive Directors of the Company are now being remunerated on normal market terms.""

Why on earth couldn"t the BOD have done something similar, and not put the company into an insolvent position by bleeding it dry!!! GL

Hope you all had a good weekend, and well the storm in London wasn"t so bad, just heavy winds and mixed with rain which is still the script. But as die hard Brits are used to that.

Was looking a bit more closely at our Interims, and my original choice of a raising in October, which I did bring forward to Early September. Well I think that was somewhat optimistic given we had a cash flow of £5.7m at end October 2019. I made the the same mistake ""again" in thinking we had more cash than expected, which would have been the case had it been end January, but just taking 500k a month cash burn to the end of February leaves us with £3.79 cash, end May £2.29m!!!

With a 25 patient trial to begin in U.S.A and U.K for SCIB1,and solving the manufacturing problem with Moditope for what we hope will be an end of year trial, I believe early 2021, the three collaborations running to Sept, Dec and January as much as I deel they will bring our first commercial deals, I doubt that will be by April2020, considering the agreements are for 12 months, so for me April/May could well be the time of our raise, with a cash balance left of circa £2.5m.

What kind of raising to expect???? Well that is always down to opinions, but in the absence of any commercial deals from Avidamab , I feel we will go for a £5/6m raise. After all if Vulpes are allowed and want to raise their stake to 30% they can buy 12.67% more, which amounts to with 495 shares in issue, another 63m shares. If that we as exercised at 6p, that would bring in about £3.8m without doing an OO as well, but that would see us through to end of year, when we will know where we stand with Avidamab and possible early results from SCIB1 trial early patients dosed, as well as anything that might become of BioNTech and Moditope. The advantage of such a raise is that when Vulpes first bought in at 5p the share was driven up to 9.75 last July, almost double the price they paid, this time on that basis why not the same with SCIB1 trial enrolling patients which should be the case by then. The 12% dilution would be set aside by any rise and I for one would support that, as long as the Company feel happy with one party owning 30% of theirs. Their could well be many other scenarios, but this one in the absence of a new party taking new issued shares at a higher price seems more realistic.

Apart from my Sept/October forecast a few others went for Q3 too, but figures don"t lie, and that is the best I can do with them. I think the Vulpes deal will be a good interim situation until we think of MOD1, as by then there could be quite a few other commercial deals coming to fruition. Importantly I don"t see the SP coming much further down, and bearing in mind we rose to 9.75 last July, we shouldn"t fear any raising. So more collaborations please, Trial site news, and support at 7p as in recent times. ATVB

I am pretty sure Ruck the BOD said a few years ago that wouldn"t happen, and the relevance of each case could be disputed by any further treatments and which one did what. It is easy to say and helps his family none that diagnosed in 2012 with a poor prognosis in stage 3.4 cancer, he lived seven years longer than anyone expected, which many cancer sufferers presumably healthy enough to have a quality life could only wish for.

I remember the two of us and Wildforce sharing those points you make about the quantity of combination trials that began some four years ago now. It was set off too by the battle between Keytruda and Opvido to get as many approvals as was possible in a pretty short time. So many trils were between same company candidates too and we doubted whether much thought had entered what was to become a race.

I agree with you 100% questioning the ethics, and putting a drain on patient numbers for all trials and lets face it how many combination therapy trials have gained Approval in perspective to how many trials that were undertaken??

The "bar has been raised"" in certain indications, certainly not in colorectal cancer and a few others, but I remember saying back then perhaps it is better to wait for a raft of results from others to compare our data with, than be too early and the big pharma waiting on others data before deciding where to invest. I noticed to in posting about changes in survival rates in the last twenty years there were so many articles of interest, immunatherapy and early detection was the reason given for many drops in incidences of death, but the data was also a bit misleading in places.'

One thing I felt sure of was we haven"t missed the boat, far from it, but early results from SCIB1/Keytruda will certainly have many trial results to compare with and just perhaps as fate would have we are going at a good time. After all Keith Flahertys interest has hardly diminished, why should ours?

So to an interesting week on here, a) do we fall out of this range 6.5/8 or b) climb back to the mid 7s. Whilst the share was walked down quickly from 16.6% up at one stage on Monday to below what we beran at Monday morning, there was hardly a rush of sellers down to 6.5p, lets see if buyers return now sub7p and around 7p as they have in recent times. GN

A very windy morning here in London town, well more than windy as it would be on my food shopping day!! Well that"s not gonna happen, lol.

Have often thought about the collaboration we had with the Karolinska Institute , the award bestowed to Lindy in Sweden, what was it....The Waldenstroff Award? Just jumped into my head.

Avidamab I would have thought would be of great interest to them..............."".AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies
by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing
properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase
the avidity or potency of any therapeutic monoclonal antibody including those being developed for
autoimmune diseases and cancer. .......................Well over at Karolinska..................https://ki.se/en/meds/autoantibody-repertoires-in-inflammatory-and-autoimmune-disease.

Just fully taking on board the enormous potential of Avidamab, and perhaps that is being shown already in the three collaborations we have signed. As they are non-exclusive agreements I guess nobody has been offered sole use by geographic position and I think we could well be underating the potential income flow from this platform.

I know this is a very difficult question, but does anybody have any idea as to what might be expected financially presuming the collaborations do turn into deals.? And I do wonder what effect this platforms potential will have on any raising in Q3, IF that timeline is correct. Considering the rises we have seen after each collaboration, and the prospects of more at any time I will go for a blue week, taking us up the 6.50/8p price range, whilst we wait for more news on trials starting. Anyone feel differently?

Other highlights from the report:
The overall rate of new cancer cases in men stayed about the same through 2016 after dropping significantly from 2007 to 2014, due to slowing declines for colorectal cancer and stabilizing rates for prostate cancer. Researchers attribute a sharp drop in prostate cancer diagnoses from 2007 to 2014 to decreased PSA testing following US Preventive Services Task Force recommendations against routine use of the test because of growing concerns about overdiagnosis and overtreatment.
The overall rate of new cancer cases in women has stayed about the same over the past few decades. While lung cancer cases have continued to decline, the drop in colorectal cancer cases has slowed and other common cancers in women have increased or stayed the same.
Breast cancer incidence rates have gone up slightly, by about 0.3% per year, since 2004. This may be due in part to increased obesity rates and decreased fertility rates.
Rates of new cases continue to increase for cancers of the kidney, pancreas, liver, and oral cavity and pharynx (among non-Hispanic whites) and melanoma skin cancer. Liver cancer is increasing fastest, by 2% to 3% annually during 2007 through 2016, although the pace has slowed from previous years.
The 5-year relative survival rate for all cancers combined that were diagnosed during 2009 through 2015 was 67% overall, 68% in whites, and 62% in blacks.
Cancer survival has improved since the mid-1970s for all of the most common cancers except cervical and endometrial cancers. A lack of improvement in survival rates largely reflect a lack of major treatment advances for patients whose cancers have spread or have come back.
“Cancer Statistics 2020” can be viewed at cacancerjournal.com, while “Cancer Facts & Figures 2020” is available at cancer.org/statistics.

Advances in treatment
The steepest declines in cancer deaths occurred for melanoma skin cancer, due in part to the immunotherapy drugs Yervoy (ipilimumab) and Zelboraf (vemurafenib), which the FDA approved in 2011. The overall melanoma death rate dropped by 7% per year during 2013-2017 in people ages 20 to 64, 1% per year in people ages 50 to 64, and 5% to 6% in people 65 and older. Progress in the 65+ age group is especially significant, because rates before 2013 had been increasing.

“The accelerated drops in lung cancer mortality as well as in melanoma that we're seeing are likely due at least in part to advances in cancer treatment over the past decade, such as immunotherapy,” said William G. Cance, MD, chief medical and scientific officer for the American Cancer Society, in a statement. “They are a profound reminder of how rapidly this area of research is expanding, and now leading to real hope for cancer patients.”

Improvements in targeted therapies and other treatments have helped drive progress for some types of leukemia and lymphoma. For example, the 5-year relative survival rate for chronic myeloid leukemia increased from 22% in the mid-1970s to 70% for those diagnosed during 2009 through 2015, and most people treated with tyrosine kinase inhibitors now have nearly normal life expectancy.

Major cancer types: Lung, breast, prostate, and colorectal cancer
The 26-year decline in overall cancer deaths is due to long-term drops in death rates in the 4 most common cancer types: lung, colorectal, breast, and prostate. Progress in reducing lung cancer deaths has improved due to declines in smoking and advances in early detection and treatment. However, progress in reducing colorectal, breast, and prostate cancers has slowed.

These 4 cancers also account for the greatest numbers of cancer deaths. Almost one-quarter of all cancer deaths are due to lung cancer, more than breast, prostate, and colorectal cancers combined.

Lung cancer death rates declined by 51% from 1990 to 2017 among men and 26% from 2002 to 2017 among women. From 2013 to 2017, the rates of new lung cancer cases dropped by 5% per year in men and 4% per year in women. The differences reflect historical patterns in tobacco use, where women began smoking in large numbers many years later than men and were slower to quit. However, smoking patterns do not appear to explain the higher lung cancer rates being reported in women compared with men born around the 1960s.
Breast cancer death rates declined 40% from 1989 to 2017 among women.
Prostate cancer death rates declined 52% from 1993 to 2017 among men.
Colorectal cancer death rates declined 53% from 1980 to 2017 among men and by 57% from 1969 to 2017 among women.

Been reading so many articles on the Internet this morning regarding progress in cancer survival rates, this is just one..............................

https://www.cancer.org/latest-news/facts-and-figures-2020.html

Freddy, well done for all you have tried to do. The odds of getting anywhere were very small. You are to be applauded.

Tell me have you been in touch with the Authorities that allow VAL to continue on AIM?? I would have felt there is a case for the share to be ""suspended"" during a review, to determine if the Directors are fit for purpose.

I am sure you have gone this route too, if not, please do, and while on the subject the evergreen Tom Winnifrith (the real crook of AIM IMHO) says very little as he has done for so long. Wonder why that was??

Try and get a few beers in Freddie, anger will destroy you, but I admire you for what you are trying to do, albeit in extra time. ATVB

And he lived to get married in July 2015.................

https://www.facebook.com/tom.worthen.96

Morning crumbs and all, I think I do get it, and I presume you are talking of the ADVFN BB more.

The SCIB1 Trial was like a cloud over us, where none of us knew when, where or how it would be restarted presuming no patients had been enrolled. So we get the news I think we all wanted to hear on Monday that the IND has been Approved at last. The share raced ahead by 17% ended the day +8%, and since then the focus for some became a funding and fears that the bar had raised too far in the time it has taken to get that Approval.

It might have helped had certain figures posted been correct, lol, and I would have hoped the bar has risen in the last 7/8 years, in many indications it has but until it has been eradicated and cured we will all continue to get the best data possible at any one given time.

As for funding, well we need an £8/10m raise as Ruck suggests, it is a great opportunity to bring all our platforms to trials and we might well be looking at Avidamab deals by Q3/Q4 too, as there are so many factors that will determine a succesful raise.

So as one cloud lifts, two others suddenly appear, c"est la vie, that is the way, but I have far from lost faith in Scancell, it feels like the business end is just beginning, and with Vulpes business clout on the BOD I feel confident in our future.

https://blog.soton.ac.uk/youreit/files/2017/11/WR_5894_UoS_YoureitFundraising_Brochure_A1_160516_V2b.pdf

Yes sad news R.I.P

For you guys here, especially for new investors. Looks to havemore to go for me. BOL

Buys 32k

Sells 26k

-2.88%.................or £1m off our M/Cap!!!......................Hopefully now the low point of the 6.50/8 range.

Have a good weekend guys